AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$NBIX

Cooke Julie sold $850K of NBIX

Cooke Julie (Chief Human Resources Officer) sold 5,466 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $155.46 ($0.85M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cooke Julie
Published Jun 4, 2026, 10:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NBIX
Neutral
high confidence
Mentioned
$NBIX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NBIXNeutralLow
01

Why it matters

The disclosure provides limited incremental information because 10b5-1 plans are designed to reduce timing-based trading signals; impact is mainly sentiment/positioning rather than fundamentals.

02

Market read

Traders may treat as a minor sentiment datapoint; the 10b5-1 qualifier lowers the probability of a strong price reaction.

03

What to watch

The filing does not indicate why the sale occurred or whether future sales/buys are planned; size relative to total holdings is modest (post-transaction 39,631 shares).

Relevance 6/10Novelty 3/10Timing: Filed 2026-06-04 after the 2026-06-02 sale date.

Background

SEC Form 4 discloses insider transactions for Neurocrine Biosciences; this specific sale was conducted via an open-market transaction under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NBIXNeutralHigh confidence
Context

Neurocrine Biosciences insider (Chief Human Resources Officer) sold $849,725 of NBIX shares under a pre-arranged 10b5-1 plan on 2026-06-02.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted given the stated 10b5-1 pre-arranged plan.

Evidence & confidence

Form 4 reports a routine open-market sale with an explicit pre-arranged 10b5-1 plan, reducing signal strength versus discretionary selling.

Market effects

Sector

No clear sector read-through; this is company-specific insider transaction data.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with periods of weaker outlook; traders may still watch for follow-on disclosures.

Key entities

  • issuer
    Neurocrine Biosciences, Inc.

    NBIX insider transaction disclosed on SEC Form 4 (Chief Human Resources Officer sale).

  • insider
    Cooke Julie

    Chief Human Resources Officer who sold 5,466 shares at $155.4566 on 2026-06-02 under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 1
$NBIXMed

Neurocrine Biosciences, Inc. Q2 2026 Earnings Call Summary

Neurocrine Biosciences reported Q2 2026 results and discussed its shift to a diversified portfolio. Management said INGREZZA record new patient additions supported raised full-year guidance midpoint for 13% YoY growth. CRENESSITY launch progress and Soleno and VYKAT XR acquisitions were highlighted. Soleno was $2.9B cash-funded; quarter-end cash was $500M and no debt.

yahoo.com7 min
JUL 31
$NBIXMedAI 8/10

Neurocrine (NBIX) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Todd Tushla Chief Executive Officer - Kyle W. Gano Chief Financial Officer - Matthew Abernethy Chief Commercial Officer - Eric S. Benevich Chief Medical Officer - Sanjay Keswani Chief Business Officer - Samir Siddhanti Need a quote from a Motley Fool analyst?

fool.com7 min
JUL 30
$NBIXHigh

NEUROCRINE BIOSCIENCES INC (NBIX): Results of Operations and Financial Condition

NEUROCRINE BIOSCIENCES INC (NBIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q2-2026xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to

SEC EDGAR 8-K6 min
JUL 9
$CRNXHighAI 9/10

Why Crinetics Stock Soared 99% This Week

Vertex (VRTX) agreed to acquire Crinetics (CRNX) for about $10B, or $85.00 per share in all cash, approved by both boards and expected to close in Q3 2026. CRNX shares rose about 99% to ~$83.54. Vertex projects the endocrine franchise could exceed $5B peak annual sales. Peers NBIX and CORT also gained on M&A expectations.

yahoo.com7 min
JUL 1
$NBIXMed

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences (Nasdaq: NBIX) began a Phase 2 open-label, single-arm study of crinecerfont (CRENESSITY) in 20 children aged 3 months to under 4 years with classic congenital adrenal hyperplasia. The 24-week trial targets safety/tolerability and will assess PK/PD biomarkers, aiming to support a supplemental NDA to expand the U.S. indication. Enrollment also reached target in a EU Phase 2 study for birth to under 2 years.

prnewswire.com4 min